Hairy cell leukemia and myelomatosis: chance association or clinical manifestations of the same B-cell disease spectrum

Catovesky, D; Costello, C; Loukopoulos, D; Fessas, PR; Foxley, JM; Traub, NE; Mills, M.J.; O'Brien, M

doi:10.1182/blood.v57.4.758.758

Cited by 38 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A very good clinical and radiological response after a single course of 2-CdA could be obtained without irradiation [22]. [18].…”

Section: Systemic Therapy Eramentioning

confidence: 93%

“…One of the most prominent clinical features is immunodepression with an increased risk of developing infections, involving mainly lung, urinary tract, liver, and CNS. Unusual complications are represented by intrathoracic and intra-abdominal lymphadenopathy [8], cutaneous involvement [9][10][11], pleural and peritoneal involvement [12], ocular [13], meningeal [14], renal [15], hernial sac localizations [16], amyloidosis [17], and paraproteinemias [3,[18][19][20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy

et al. 2007

View full text Add to dashboard Cite

Skeletal localizations are a rare complication in hairy cell leukaemia patients, with an extimated incidence of 3%. These lesions, mainly osteolytic, can occur at various sites and are almost always symptomatic. Localized radiation therapy (RT) has been extensively used as effective palliative treatment in such cases, with different total doses and fractionation schedules. In this article, a systematic review of all reported cases with osseous complications is presented, to underline the role of RT and to define the most appropriate approach in this subset of patients. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.

show abstract

“…A very good clinical and radiological response after a single course of 2-CdA could be obtained without irradiation [22]. [18].…”

Section: Systemic Therapy Eramentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Simultaneous or subsequent occurrence of HCL with multiple myeloma has also been reported, albeit rarely (Catovesky et al, 1981;Kurzrock et al, 1997;Flinn et al, 2000;Saif & Greenberg, 2001). It is not known whether the subsequent occurrence of these two entities represents a transformation of HCL into a more differentiated B-cell malignancy, a biclonal neoplasm arising from an oncogenic event in a common B-cell precursor or whether this represents an independent oncogenic event due to the defect in immune dysregulation.…”

Section: Discussionmentioning

confidence: 99%

“…It is not known whether the subsequent occurrence of these two entities represents a transformation of HCL into a more differentiated B-cell malignancy, a biclonal neoplasm arising from an oncogenic event in a common B-cell precursor or whether this represents an independent oncogenic event due to the defect in immune dysregulation. Immunodeficiency associated with B-cell dysfunction is known to be linked with various cancers (Catovesky et al, 1981;Lawlor et al, 1984;Aronowitz, Baral & Dalal, 1993;Kurzrock et al, 1997;Saif & Greenberg, 2001).…”

Section: Discussionmentioning

confidence: 99%

“…It is predominantly lytic in nature and shows a predilection for the axial skeleton, particularly the neck of femur region. Rarely, bone involvement occurs at initial presentation, although it more commonly develops during the course of untreated disease or in patients treated with splenectomy alone (Catovesky et al, 1981;Lembersky, Ratain & Golomb, 1988). It is therefore understandable to attribute lytic lesions seen in a patient with HCL to this disease and not some other occult neoplasm.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of Mollitias and Fragilitas Ossium – unusual presentation of hairy cell leukaemia followed by the diagnosis of nonsecretory myeloma

Besser

Goonetileke

Min

et al. 2008

Int J Lab Hematology

View full text Add to dashboard Cite

Hairy cell leukaemia (HCL) is a B-cell malignancy with a late developmental arrest. This report describes a patient that presented with leucocytosis and splenomegaly. The abnormal leucocytes showed typical morphology and expressed CD103, CD11c, CD19 and CD20 but not CD25 by immunophenotyping. The patient failed to respond to splenectomy and then developed lytic bone lesions and pathological fractures, which progressed despite a single course of cladribine chemotherapy. Review of the pathology of the bone reamings showed nonsecretory myeloma of the same kappa-light chain isotype. He went on to receive induction chemotherapy in preparation for an autologous stem-cell transplant but failed to mobilize sufficient numbers of stem cells. He has had two localized relapses with bony lesions, one within 6 weeks of stopping chemotherapy for which he received localized radiotherapy and thalidomide consolidation. Sequential myeloma has been described in HCL. There is controversy whether this represents clonal evolution or a secondary malignancy. An increased rate of secondary malignancies has been reported by some, but not other, authors in long-term survivors of HCL. This case illustrates the value of a repeat pathological review in case of unexpected complications.

show abstract

Second malignancies in hairy cell leukemia

Jacobs

Vokes

Golomb

1985

Cancer

View full text Add to dashboard Cite

Among 172 patients with hairy cell leukemia (HCL) seen at the University of Chicago over a 10-year period, 15 were found to have a second malignancy. Neoplasia of the skin was noted most frequently; there were three cases of basal cell carcinoma, one case of anaplastic squamous cell carcinoma, and one case of malignant melanoma. This was followed in frequency by three cases of carcinoma of the lung. The clinical characteristics of these 15 patients did not differ from those of the general population of patients with HCL. A variety of second hematologic malignant disorders and solid tumors were identified. In one case, the second neoplasm occurred before the diagnosis of HCL; six were diagnosed concurrently; and eight followed the diagnosis of HCL. Since HCL is a well-defined clinicopathologic entity, patients with HCL who exhibit unusual features of the disease should be investigated further for the presence of second malignancies.Cancer 56:1462-1467, 1985. AIRY CELL LEUKEMIA (HCL) is a well-defined clin-H icopathologic entity characterized by the presence of abnormal circulating mononuclear cells with large cytoplasmic projections.' Patients often have initial symptoms related to cytopenias, as well as massive splenomegaly and absent or minimal lymphadenopathy.',' The disease has a chronic course; however, progressive infiltration of bone marrow by hairy cells can occur. Granulocytopenia and monocytopenia are known to predispose patients to a variety of infectious complications.'~~ When cytopenias exist, splenectomy is generally regarded as appropriate initial therapy. ' The origin of hairy cells remains a subject of continued debate. Generally, HCL is considered to be a B-cell neoplasm'; however, hairy cells also have monocytic features7** The occurrence of second malignancies in HCL noted in published reports has led to further questions regarding the etiology of HCL. In addition, the presence of a second malignancy can complicate the management of the patient. In this report, we describe second malignancies in 15 patients with HCL. Materials and MethodsWe reviewed the records of all patients with hairy cell leukemia who were referred to the University of Chicago from 1975 through February 1984. Of 172 patients who were identified, 15 had a malignant disease in addition to HCL. We recorded patient sex, age at diagnosis of HCL, the nature of the second malignancy, the interval to the diagnosis of the second malignancy, the treatment for HCL and the other disease, and the hematologic status of the patients with HCL at the time the second malignancy was diagnosed. When splenectomy was undertaken within I month of the diagnosis of HCL, it was considered as being done at the time of diagnosis. The second malignancy and HCL were considered to be concurrent if they were diagnosed within 12 months of each other. ResultsPatient characteristics, as well as data on the diagnosis and treatment of HCL and the nature of the second malignancy, are summarized in Table 1. In our series, there were 14 men and 1 woman. The ag...

show abstract

Hairy cell leukemia and myelomatosis: chance association or clinical manifestations of the same B-cell disease spectrum

Cited by 38 publications

References 0 publications

Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy

Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy

A case of Mollitias and Fragilitas Ossium – unusual presentation of hairy cell leukaemia followed by the diagnosis of nonsecretory myeloma

Second malignancies in hairy cell leukemia

Contact Info

Product

Resources

About